Abstract
A 35-year-old woman with a history of breast cancer, treated 3 years ago with surgery, radiation, and chemotherapy presented with a rapid onset of severe Raynaud’s phenomenon. On physical examination, she had digital ulcers and splinter hemorrhages; there were no signs of an underlying rheumatic condition. Laboratory evaluation revealed anemia, the presence of antinuclear antibody and slight depression in her serum complement C3 level. The remainder of her serologic evaluation, including extractable nuclear antigens, anti-double-stranded DNA antibody, antiphospholipid antibodies, rheumatoid factor, anti-neutrophil cytoplasmic antibodies, cryoglobulins, and cold agglutins, were negative. Within weeks of her presentation, she developed acute renal failure and bilateral lower extremity edema. A computed tomography scan of her abdomen and pelvis showed bulky lymphadenopathy and hydronephrosis; a pelvic lymph node biopsy revealed metastatic breast cancer. She was initially managed with passive rewarming strategies, topical antibiotics, vasodilator and anti-platelet therapy, but had a negligible response. However, once she was started on chemotherapy for her recurrent malignancy, there was a significant improvement in her Raynaud’s symptoms and resolution of her digital ulcers.
References
Silman A, Holligan S, Brennan P, Maddison P (1990) Prevalence of symptoms of Raynaud’s phenomenon in general practice. BMJ 301:590–592
Wigley FM (1993) Raynaud’s phenomenon. Curr Opin Rheumatol 5:773–784. doi:10.1097/00002281-199305060-00013
Planchon B, Pistorius MA, Beurrier P, De Faucal P (1994) Primary Raynaud’s phenomenon: age of onset and pathogenesis in a prospective study of 424 patients. Angiology 45:677–686. doi:10.1177/000331979404500802
Racanelli V, Prete M, Minoia C et al (2008) Rheumatic disorders as paraneoplastic syndromes. Autoimmun Rev 7:352–358. doi:10.1016/j.autrev.2008.02.001
Papasavvas G, Goodwill CJ (1989) Scleroderma and breast Carcinoma. Br J Rheumatol 4:366–367. doi:10.1093/rheumatology/28.4.366
Forbes AM, Woodrow JC, Verbov JL, Graham RM (1989) Carcinoma of breast and scleroderma; four further cases and a literature review. Br J Rheumatol 28:65–69. doi:10.1093/rheumatology/28.1.65
De Angelis R, Silveri F, Bugatti L et al (2003) Raynaud’s phenomenon after combined chemotherapy. Chemotherapy 49:267–268. doi:10.1159/000072453
Wigley FM, Hummers LK (2003) Management of Raynaud’s phenomenon and digital ischemic lesions in scleroderma. Rheum Dis Clin North Am 29:293–313. doi:10.1016/S0889-857X(03)00019-X
Papamichael D, Amft N, Slevin ML et al (1998) 5-Fluorouracil-induced Raynaud’s phenomenon. Eur J Cancer 34:1983. doi:10.1016/S0959-8049(98)00184-1
Berger CC, Bokemeyer C, Schneider M, Kuczyk MA, Schmoll HJ (1995) Secondary Raynaud’s phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer 31A(13–14):2229–2238. doi:10.1016/0959-8049(95)00460-2
Reiser M, Bruns C, Hartmann P, Salzberger B, Diehl V, Fatkenheuer G (1998) Raynaud’s phenomenon and acral necrosis after chemotherapy for AIDS-related Kaposi’s sarcoma. Eur J Clin Microbiol Infect Dis 17(1):58–60. doi:10.1007/BF01584368
Candelaria M, Hurtado-Monroy R, Vargas-Viveros P, Carrillo-Munnoz S, Duenas-Gonzalez A (2007) Tamoxifen-associated vasculitis in a breast cancer patient. World J Surg Oncol 5:9. doi:10.1186/1477-7819-5-9
Baptista MZ, Prieto VG, Chon S, Hortobagyi GN, Esteva FJ (2006) Tamoxifen-related vasculitis. J Clin Oncol 24(21):3504–3505. doi:10.1200/JCO.2005.05.3322
Betto P, Gennari E, Germi L, Bonoldi E, Scalco G, Tosti A (2008) Tamoxifen and purpuric vasculitis: a case report. J Eur Acad Dermatol Venereol 22(6):762–763. doi:10.1111/j.1468-3083.2007.02479.x
Toumbis-Ioannou E, Cohen PR (1994) Chemotherapy-induced raynaud’s phenomenon. Cleve Clin J Med 3:195–199
Szekanecz E, Andras C, Sandor Z, Antal-Szalmas P, Szanto J, Tamasi L et al (2006) Malignancies and soluble tumor antigens in rheumatic diseases. Autoimmun Rev 6:42–47. doi:10.1016/j.autrev.2006.03.007
Adamus G (2003) Autoantibody-induced apoptosis as a possible mechanism of autoimmune retinopathy. Autoimmun Rev 2:63–68. doi:10.1016/S1568-9972(02)00127-1
Saiki M, Sakai K, Saiki S, Kitagawa Y, Nakanishi M, Hirose G (2005) Induction of humoral responses specific for paraneoplastic cerebellar degeneration-associated antigen by whole recombinant yeast immunization. J Autoimmun 24:203–208. doi:10.1016/j.jaut.2005.01.008
Lorusso L, Hart KI, Ferrari D, Ngonga KG, Gasparetto C, Ricevuti G (2007) Autonomic paraneoplastic neurological syndromes. Autoimmun Rev 6:162–168. doi:10.1016/j.autrev.2006.10.003
Hansen SW, Olsen N (1989) Raynaud’s phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: measurement of vasoconstrictor response to cold. J Clin Oncol 7(7):940–942
Acknowledgments
Written consent for publication was obtained from the patient.
Conflict of interest statement
The authors have no competing interests.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Allen, D., Robinson, D. & Mittoo, S. Paraneoplastic Raynaud’s phenomenon in a breast cancer survivor. Rheumatol Int 30, 789–792 (2010). https://doi.org/10.1007/s00296-009-0985-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-009-0985-5